Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe it's 30 months bc that's when the patents will end. The time won't matter bc IPCI will either win or settle for paying a licensing fees.
SequestOx is a legitimate threat to Big Pharma. That's what is slowing it down. RoxidBond isn't a serious threat.
The CEO talked about the possibility of a RS, but he also talked about waiting until the pps was at $2.
So then you agree Nasrat said goal and not promise. A goal is not a promise nor a guarantee.
Elite Pharmaceuticals has a deal with Epic for SequestOx. Nasrat has strongly hinted at updated deal with Pura coming soon.
True but the point is that Nasrat stated it was a goal to file one every quarter. He never promised nor guaranteed one within specific dates of each quarter and anything to contrary is a lie that should be confronted. The debate is ridiculous anyway until the quarter is actually over.
Maybe you can find a list of patents that weren't filed after Elite filed for their patents. That first one is laughable. Elite's abuse resistant patent was filed several years before Purdue filed 9,456,989.
I think Nasrat intentionally said by end of the year to give a lot of extra time and also to take a subtle jab.
It's too soon to say how a delay would affect the share price. We'll have some CC's between now and then that would determine things. I fully expect they'll resubmit by early to mid fall.
Most importantly, the data from the current BE trial is going to affect the share price long before resubmitting, and we'll also have the following BE trial data before resubmitting.
I see nothing in August of 2013 where ELTP was in the teens.
resubmitting in June would be by year's end.
No he didn't.
No, I don't believe the BS. I do believe the truth that Elite got screwed by a corrupt FDA head.
We have 0% of those markets at the moment. Which one of those do we have in the market? We'll get them eventually, but it's total bs to say we own them now.
there is absolutely no way we'll be anywhere near 2.75 at launch. We won't even be at .75. We're going to need serious revenue before this thing starts moving.
Which specific fact is nonsensical? None.
You have no idea what deal he was offered so there is no way to know if it was a mistake or not. He clearly said the other company wanted the right of first refusal and that he wasn't giving away a billion dollar technology for the price of one drug.
There is certainly no way for March 31, but I also don't think it takes anywhere close to end of the year to resubmit. Nasrat did say few months, but he did not say it "here and there".
Page 5 of transcripts
You are correct. Nasrat said will be initiated this quarter:
This is from the press release on Elite's website
How would your scenario work for someone who suddenly felt a lot of pain in the middle of a fatty meal or immediately after a fatty meal? That person would have to wait 2 hours. Don't think anyone is going to wait 2 hours. Waiting 2 hours doesn't equal immediate release.
There's a big difference between a buyout after approval and a buyout being imminent. Approval isn't even imminent, so a buyout certainly can't be imminent. They are both inevitable but not imminent.
a buyout is not imminent. Why even say that nonsense?
You can't say it's a fact that SequestOx has clear path forward. The 8K said "the Company believes" we have a clear path forward.
Yes, he would need to convert if they are discussions for a major partnership or buyout. Most large companies will not get into deep negotiations until all preferred shares are eliminated.
None of those details mean anything. Shareholders still made over 700% profit.
The ceo, Hakim, recently converted his preferred shares to common shares. All preferred shares are almost always eliminated in one fashion or another when a major partnership or buyout is going to occur. There may or may not be a buyout, but there is probably some big reason Hakim converted those shares.
Sungen's webpage making ability has zero to do with their business model.
Hasn't TapImmune reverse split 2 or 3 times before?
Why does this matter:
here's a nice quote:
Then why have labels at all? We need all drugs that require no labels since people are too stupid to follow directions on a label. Albeit, we have no record of anyone ever dying from this scenario:
Absolute worst case scenarios are either re-engineering or reducing the high dosage forms. Even if it takes a few years, it will still get resolved. Approval is guaranteed.
A more likely worst case scenario is Gene handles this "legally" behind closed doors. I'm confident the FDA wants SequestOx to be approved, but I'm also confident they want to stall SequestOx. They will stall for a while longer and then approve it.
I agree, approval is a foregone conclusion. Let's get back to discussing market penetration and revenues. Look past this small, meaningless obstacle.
You told yourself you are wrong. Brilliant.
Say it as many times as you like, but you are wrong every single time
I agree with you about giving us a clue, but if it's a clue, that could mean an adcom, which isn't the worst thing. I think the reference to September was for a possible adcom meeting, probably not for approval.